|
|
Cost-effectiveness of novel multiple sclerosis drug
| Third-party funded project |
| Project title |
Cost-effectiveness of novel multiple sclerosis drug |
| Principal Investigator(s) |
Schwenkglenks, Matthias
|
| Co-Investigator(s) |
Szucs, Thomas
|
| Project Members |
Bhadhuri, Arjun
Schur, Nadine
|
| Organisation / Research unit |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
| Project start |
10.12.2018 |
| Probable end |
31.12.2019 |
| Status |
Completed |
| Abstract |
Assessment of cost-effectiveness of a novel multiple sclerosis drug, from the perspective of the Swiss statutory health insurance and Swiss healthcare system. |
| Financed by |
Private Sector / Industry
|
Published results () |
| |
ID |
Autor(en) |
Titel |
ISSN / ISBN |
Erschienen in |
Art der Publikation |
|
4618252 |
Schur, Nadine; Gudala, Kapil; Vudumula, Umakanth; Vadapelle, Sreelatha; Bhadhuri, Arjun; Casanova, Alain; Adlard, Nicholas; Schwenkglenks, Matthias |
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland |
1170-7690 ; 1179-2027 |
PharmacoEconomics |
Publication: JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) |
|
| |
|
|
MCSS v5.8 PRO. 0.471 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
20/04/2024
Research Database / FORSCHUNGSDATENBANK
|
